Uniworth International reports FY26 net loss of ₹156.91 lakh
Uniworth International Limited reported a consolidated net loss of ₹156.91 lakh for the financial year ended March 31, 2026, compared to a loss of ₹157.73 lakh in the previous year. Revenue from operations remained nil, while other income was ₹0.41 lakh. Khandelwal Ray & Co., the statutory auditor, issued a qualified opinion due to the non-provision of doubtful assets, including trade receivables of ₹3,010.57 lakh and other financial assets of ₹227.73 lakh. The auditor also noted an inability to obtain sufficient evidence regarding the investment in subsidiary Uniworth Biotech Limited. Total expenses decreased to ₹157.33 lakh, and the company's net worth remained negative at ₹1,202.55 lakh.
*this image is generated using AI for illustrative purposes only.
Uniworth International Limited reported a consolidated net loss of ₹156.91 lakh for the financial year ended March 31, 2026, narrowing slightly from the loss of ₹157.73 lakh recorded in the previous year. The company's standalone net loss for FY26 stood at ₹157.01 lakh. Total revenue from operations remained nil, while other income for the consolidated entity was reported at ₹0.41 lakh. The Board of Directors approved the audited standalone and consolidated financial results at a meeting held on May 29, 2026.
Khandelwal Ray & Co., the statutory auditor, issued a qualified opinion on the standalone and consolidated financial results. The qualification arises primarily from the non-provision of certain debts and current assets considered doubtful of recovery. Specifically, the auditor noted no provision was made for trade receivables amounting to ₹3,010.57 lakh, other financial assets of ₹227.73 lakh, and loans to body corporates of ₹0.41 lakh. Additionally, no provision was made for an investment of ₹5.12 lakh in a sick and delisted company, TDS receivable of ₹13.95 lakh, and miscellaneous advances of ₹53.39 lakh.
The consolidated financial statements include the results of Uniworth Biotech Limited, a subsidiary acquired during the year. The auditor reported being unable to obtain sufficient appropriate audit evidence regarding the carrying amount of the investment in this subsidiary, amounting to ₹4.93 lakh, due to denied access to financial information and management. Consequently, the auditor could not determine if adjustments were necessary for the subsidiary's net profit of ₹0.07 lakh included in the consolidated results.
Total expenses for the consolidated entity decreased marginally to ₹157.33 lakh in FY26 from ₹157.73 lakh in the previous year. The company's net worth stood at a negative ₹1,202.55 lakh in the consolidated results as of March 31, 2026. Management noted that business activities have been suspended for a long period and that no notional income or expenditure arising from foreign currency gains or losses was accounted for due to uncertainty regarding the realization of export trade receivables. The company has not recognized deferred tax assets in view of consistent losses.
Financial Performance Summary
| Metric | Consolidated FY26 (₹ in Lacs) | Consolidated FY25 (₹ in Lacs) | Standalone FY26 (₹ in Lacs) | Standalone FY25 (₹ in Lacs) |
|---|---|---|---|---|
| Total Revenue | 0.41 | - | - | - |
| Total Expenses | 157.33 | 157.73 | 157.01 | 157.17 |
| Net Profit/(Loss) | (156.91) | (157.73) | (157.01) | (157.17) |
| Basic & Diluted EPS | (1.05) | (1.06) | (1.05) | (1.05) |
Does Uniworth International have a specific turnaround strategy to resume business operations given the long suspension of activities?
How does the company plan to address the statutory auditor's qualified opinion regarding the non-provision of doubtful debts?
What steps will management take to resolve the lack of access to financial information at the subsidiary, Uniworth Biotech Limited?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
